PolyNovo publishes its FY26 Annual Report
The report includes leadership insights, patient stories, and updates on ESG initiatives alongside financial data.
See the latest news and media coverage for PolyNovo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of synthetic skin substitutes
polynovo.comLast updated
In short: PolyNovo reported record FY26 revenue of $150 million, expanded to 50 countries, and underwent several key leadership transitions.
The report includes leadership insights, patient stories, and updates on ESG initiatives alongside financial data.
His prior leadership roles at CSL Seqirus bring over a decade of pharmaceutical and biotechnology expertise to support the company's global scaling initiatives.
The organization expands its NovoSorb platform to over fifty countries while leveraging a robust evidence base of five hundred thirty clinical publications.
The executive joins from North America with healthcare experience to accelerate commercial growth and international brand development.
29/05 PolyNovo: the filing of the US PMA application for NovoSorb BTM now expected by end of 2026; the stock falls by...
PolyNovo Limited (CALZF) Q4 2026 Earnings Call August 25, 2026 8:30 PM EDTCompany ParticipantsBruce Peatey - Chief Executive OfficerJan-Marcel Gielen - CFO...
PolyNovo (ASX: PNV) delivered FY26 revenue up 16.1% to $150 million and posted a $7.3 million profit. Expansion of manufacturing and strong cash flow continue.
PolyNovo (ASX:PNV) develops biodegradable wound-care technologies through its NovoSorb platform.
Track PolyNovo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to PolyNovo and other trending companies.